Cannabinoid–NMDA Interaction Changed With the Tested Mixture Ratio
A cannabinoid agonist and an NMDA antagonist attenuated morphine tolerance additively at some tested ratios and supra-additively at another. Synergy was a property of a specified combination, not a universal label.
The outcome was tolerance attenuation
The study compared CP55,940, LY235959 and fixed-proportion mixtures during repeated morphine exposure in mice. It used dose-addition and isobolographic analysis. CP55,940 is a synthetic cannabinoid agonist; LY235959 is not cannabis.
The reference model supplied the test
The investigators compared experimental mixture potency with the potency predicted under additivity. Two ratios were consistent with additive effects; the more NMDA-antagonist-heavy ratio showed a supra-additive result. Merely outperforming one component would not have established that conclusion.
Keep the target outcome attached
Attenuating a later tolerance shift is not the same as increasing acute analgesia, preventing overdose or reducing drug taking. The tested doses, ratios and laboratory endpoint constrain the claim. These findings do not establish that THC-containing products combined with other medications are synergistic. A useful review asks which mixture, which response and which mathematical reference supported the interaction description before transferring it to clinical care.
Related analysis: Cannabis Tolerance Claims: Questions to Ask Before Relying on Expert Testimony.
Primary research
Attenuation of morphine antinociceptive tolerance by a CB(1) receptor agonist and an NMDA receptor antagonist: Interactive effects. Neuropharmacology (2010). DOI: 10.1016/j.neuropharm.2009.08.005.
